A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Trial Profile

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin glargine
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DEVOTE
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 14 Jun 2017 According to a Novo Nordisk media release, the company has submitted a Type II Variation application to the European Medicines Agency (EMA) for including data in the label for Tresiba (insulin degludec) from this trial.
    • 12 Jun 2017 Results published in a Novo Nordisk media release.
    • 12 Jun 2017 According to a Novo Nordisk media release, results from this trial were presented at the American Diabetes Association's 77th Scientific Sessions (ADA 2017) and also published simultaneously in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top